SBIR/STTR Research Award
Robust, defined, animal-free cell culture medium for the production of vaccines
Award amount
$1,516,871Program and phase
SBIR · Phase IIAward year
2012Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VENTRIA BIOSCIENCE
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA11-096
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): The Vero cell line is used in the production of viral based vaccines. The use of cell based vaccines based on the Vero cell line is growing. The majority of the vaccines in use today are produced using cell culture medium supplemented with serum. The use of animal-derived products in vaccine culture media presents a risk for the transmission of infectious disease on a wide scale. Current commercially available serum-free vaccine media are not defined, inconsistent, and do not offer the same performance as media supplemented with serum. We propose to produce a superior performance, defined, animal-free, cell culture medium for vaccine production. Our project addresses the call by agencies for a safe alternative to animal-derived components in vaccine production. PUBLIC HEALTH RELEVANCE: Epithelial cell lines such as Vero are used in the manufacture of viral based vaccines and their use is expanding. Current commercially available animal-free vaccine production media are not defined and do not offer the same performance as media supplemented with serum. We propose the industry's first defined, high performance animal-free, cell culture medium to increase the safety and the production of vaccines.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients